Biotech News - Congoo

LOS ANGELES (Reuters) - Gilead Sciences Inc reported an 8.6 percent increase in second-quarter profit on Thursday, driven by higher sales of its drugs that fight the virus that causes AIDS. But the results

Bellus Health signs agreement to acquire Innodia - 10 Hours ago

Bellus Health Inc. (formerly known as Neurochem Inc.) has signed a definitive agreement to purchase capital stock of Innodia Inc. This will result in the Bellus Health Group owning 100 per cent of the

all 8 news articles >>

Sales of Vancouver biotech's eye drug continue to decline as global competition - 11 Hours ago

Sales of QLT Inc.'s (TSX:QLT) macular degeneration drug continued to fall in the second quarter of 2008. Global Visudyne sales dropped 31.5% to US$40.7 million for the quarter ending June 30 from US$59.3

Electronic biometric passports to introduced in Kazakhstan - 11 Hours ago

Kazakhstan is set to be the first CIS country to introduce biometric passports with a corresponding statement having been made at a meeting of the Ministry for Justice in Almaty. First samples have passed

all 3 news articles >>

OGI and Invitrogen bring epigenomics to the fore in Genome 2.0 symposium - 14 Hours ago

The Ontario Genomics Institute (OGI) teamed up with Invitrogen Corporation, a California-based global leader in providing life sciences technology, to host Genome 2.0: New Frontiers in Epigenomics, a

Jubilant, Amgen Enter Drug Discovery Deal - 16 Hours ago

Email This Page Copyright Permissions Comment on This Story Custom Reprints Current Issue View Archives More Pharmaceuticals & Fine Chemicals Lonza to Co-Develop Novartis Biologics Pipeline Riemser

Ernst & Young - The right transaction

Sponsored

No matter what the size of your company, where it is located or the business you are in, transactions can help your company grow, prosper or reinvent itself. The Ernst and Young Transaction professionals can play a critical role at every step of the deal lifecycle. Learn More

Gilead numbers €uninspiring€™ - 17 Hours ago

TheStreet's Adam Feuerstein rated Gilead Science's second quarter numbers 'uninspiring,' with strong top-line results and a disappointment in earnings. As one of the few profitable biotechs in the market,

Still Liking Gilead, Warts and All - 17 Hours ago

After another quarter in the books, it's still tough find much to complain about with drug company Gilead Sciences (Nasdaq: GILD). On Thursday, Gilead posted second-quarter numbers, showing no major cracks

Baxter International Inc. Q2 2008 Earnings Call Transcript - 4 Hours ago

8:30 am ET Executives Mary Kay Ladone - VP of IR Bob Parkinson - CEO Rob Davis - CFO Analysts Larry Keusch - Goldman Sachs Mike Weinstein - JPMorgan Ben Andrew - William Blair Mat